Prognostic impact of C-reactive protein in metastatic prostate cancer: A systematic review and meta-analysis

Oncology Research and Treatment

Volumn 37, Issue 12, 2014, Pages 772-776

  Rocha, Pedro ^a   Morgan, Charity J ^b   Templeton, Arnoud J ^c   Pond, Gregory R ^d   Naik, Gurudatta ^e   Sonpavde, Guru ^e  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d MCMASTER UNIVERSITY   (Canada)

^e University of Alabama at Birmingham   (United States)

Author keywords

C reactive protein; Metastatic disease; Prognostic factor; Prostate cancer

Indexed keywords

ABARELIX; C REACTIVE PROTEIN; CALCITRIOL; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; GONADORELIN ANTAGONIST; IMATINIB; ISOSORBIDE; PLACEBO; PREDNISONE; ZOLEDRONIC ACID; C-REACTIVE PROTEIN;

ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CASTRATION SENSITIVE PROSTATE CANCER; CONFIDENCE INTERVAL; HAZARD RATIO; HUMAN; META ANALYSIS; METASTATIC PROSTATE CANCER; ORCHIECTOMY; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW; BLOOD; HUMANS; MALE; METABOLISM; MORTALITY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

C-REACTIVE PROTEIN; HUMANS; MALE; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84919790137     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000369545     Document Type: Review

References (39)

1. Armstrong AJ, Garrett-Mayer ES, Yang YC, et al.: A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-403.
2. Armstrong AJ, Tannock IF, de Wit R, et al.: The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010; 46: 517-25.
3. Halabi S, Lin CY, Small EJ, et al.: Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst 2013; 105: 1729-37.
4. Soloway MS, Hardeman SW, Hickey D, et al.: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.
5. Imai K, Tomaru Y, Ohnuki T, et al.: Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis. Cancer 1992; 69: 2983-9.
6. De Bono JS, Scher HI, Montgomery RB, et al.: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9.
7. Scher HI, Heller G, Molina GA, et al.: Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo- controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011; 29(suppl):abstr LBA4517.
8. Kantoff PW, Higano CS, Shore ND, et al.: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
9. Beer TM, Lalani AS, Lee S, et al.: C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008; 112: 2377-83.
10. Prins RC, Rademacher BL, Mongoue-Tchokote S, et al.: C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol 2012; 30: 33-7.
11. Liberati A, Altman DG, Tetzlaff J, et al.: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62:e1-34.
12. Schwarzer G: Meta-Analysis with R. R package version 2.3-0, 2013. CRANR-projectorg/package= meta.
13. Viechtbauer W: Conducting meta-analyses in R with the metafor package. J Stat Soft 2010; 36: 1-48.
14. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
15. Higgins JP, Thompson SG, Deeks JJ, et al.: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
16. Pond GR, Armstrong AJ, Wood BA, et al.: Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int 2012; 110:E461-8.
17. Ito M, Saito K, Yasuda Y, et al.: Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology 2011; 78: 1131-5.
18. Nakashima J, Kikuchi E, Miyajima A, et al.: Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol Int 2008; 80: 129-33.
19. McArdle PA, Mir K, Almushatat AS, et al.: Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006; 77: 127-9.
20. Sutton AJ, Song F, Gilbody SM, et al.: Modelling publication bias in meta-analysis: a review. Stat Methods Med Res 2000: 9:421-45.
21. Liu ZQ, Chu L, Fang JM, et al.: Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl 2014; 16: 467-71.
22. Guo YZ, Pan L, Du CJ, et al.: Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev 2013; 14: 243-8.
23. Tartour E, Dorval T, Mosseri V, et al.: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 69: 911-3.
24. Nozoe T, Matsumata T, Kitamura M, et al.: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998; 176: 335-8.
25. Legouffe E, Rodriguez C, Picot MC, et al.: C-reactive protein serum level is a valuable and simple prognostic marker in non-Hodgkin's lymphoma. Leuk Lymphoma 1998; 31: 351-7.
26. Nozoe T, Saeki H, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001; 182: 197-201.
27. Polterauer S, Grimm C, Tempfer C, et al.: C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 2007; 107: 114-7.
28. Schmid M, Schneitter A, Hinterberger S, et al.: Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer. Obstet Gynecol 2007; 110: 1231-6.
29. Hefler LA, Concin N, Hofstetter G, et al.: Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008; 14: 710-4.
30. Tatokoro M, Saito K, Iimura Y, et al.: Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol 2008; 180: 515-9.
31. Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.
32. De Marzo AM, Marchi VL, Epstein JI, et al.: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-92.
33. Dennis LK, Lynch CF, Torner JC: Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60: 78-83.
34. Du Clos TW: Function of C-reactive protein. Ann Med 2000; 32: 274-8.
35. Thomas-Rudolph D, Du Clos TW, et al.: C-reactive protein enhances immunity to Streptococcus pneumoniae by targeting uptake to Fc gamma R on dendritic cells. J Immunol 2007; 178: 7283-91.
36. Keizman D, Gottfried M, Ish-Shalom M, et al.: Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist 2012; 17: 1508-14.
37. Sonpavde G, Pond GR, Armstrong AJ, et al.: Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2014; 12: 317-24.
38. Templeton AJ, McNamara MG, Seruga B, et al.: Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106:dju124.
39. Vigushin DM, Pepys MB, Hawkins PN: Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993; 91: 1351-7.